| 摘要: |
| 目的：观察二陈汤加减联合奥沙利铂+替吉奥（SOX）方案治疗晚期胃癌的临床疗效及其对患者炎症因子水平和生存质量的影响。方法：选取60例晚期胃癌患者，将其随机分为治疗组和对照组，每组各30例。对照组采用SOX方案治疗，治疗组在对照组基础上加用二陈汤加减治疗。比较2组疾病缓解率、中医证候评分、炎症因子［肿瘤坏死因子-α（tumor necrosis factor-α，TNF-α）、白细胞介素-6（interleukin-6，IL-6）、白细胞介素-10（interleukin-10，IL-10）］水平、生命质量测定量表（Quality of Life Measurement Scale，EORTC QLQ-C30）评分和不良反应发生情况。结果：疾病缓解率治疗组为80.00%（24/30），对照组为53.33%（16/30），2组比较，差异有统计学意义（P<0.05）；2组中医证候评分、炎症因子水平、EORTC QLQ-C30评分治疗前后组内比较及治疗后组间比较，差异均有统计学意义（P<0.05）；不良反应发生率治疗组为13.33%（4/30），对照组为6.67%（2/30），2组比较，差异无统计学意义（P>0.05）。结论：二陈汤加减联合SOX方案治疗晚期胃癌，可协同提升疾病缓解率，降低中医证候评分，改善炎症指标与生活质量，且安全性良好，值得临床推广。 |
| 关键词: 胃癌 晚期 中西医结合疗法 二陈汤加减 SOX方案 炎症因子 生存质量 |
| DOI： |
|
|
| Clinical effect of modified Erchen decoction combined with the regimen of oxaliplatin, tegafur, gimeracil, and oteracil potassium in treatment of advanced gastric cancer: An analysis of 30 cases |
| TONG Ruimin |
| (People’s Hospital of Yangzhong City, Yangzhong 212200, Jiangsu, China) |
| Abstract: |
| Objective: To investigate the clinical effect of modified Erchen decoction combined with the regimen of oxaliplatin, tegafur, gimeracil, and oteracil potassium （SOX regimen） in the treatment of advanced gastric cancer, as well as its effect on the levels of inflammatory factors and quality of life. Methods: A total of 60 patients with advanced gastric cancer were randomly divided into treatment group and control group, with 30 patients in each group. The patients in the control group were treated with the SOX regimen, and those in the treatment group were given modified Erchen decoction in addition to the treatment in the control group. The two groups were compared in terms of disease remission rate, traditional Chinese medicine （TCM） syndrome score, inflammatory factors （tumor necrosis factor-α ［TNF-α］, interleukin-6 ［IL-6］, and interleukin-10 ［IL-10］）, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 （EORTC QLQ-C30） score, and adverse reactions. Results: There was a significant difference in disease remission rate between the treatment group and the control group ［80.00% （24/30） vs 53.33% （16/30）, P<0.05］. After treatment, both groups had significant changes in TCM syndrome score, the levels of inflammatory factors, and EORTC QLQ-C30 score, and there were significant differences in these indicators between the two groups after treatment （P<0.05）. There was no significant difference in the incidence rate of adverse reactions between the treatment group and the control group ［13.33% （4/30） vs 6.67% （2/30）, P>0.05］. Conclusion: In the treatment of advanced gastric cancer, modified Erchen decoction combined with the SOX regimen can synergistically increase disease remission rate, alleviate TCM syndrome, and improve inflammatory markers and quality of life, with a favorable safety profile, and therefore, it holds promise for clinical application. |
| Key words: gastric cancer advanced integrated traditional Chinese and Western medicine therapy modified Erchen decoction oxaliplatin, tegafur, gimeracil, and oteracil potassium regimen inflammatory factor quality of life |
